Making strides in oncology immunotherapy: Scancell's Richard Goodfellow discusses lead product
UK-based oncology specialist Scancell (AIM: SCLP) is aiming to break ahead of the cancer immunotherapy pack. Richard Goodfellow, joint chief executive of the company, discussed his optimism around its lead product, SCIB1.
He calls oncology immunotherapy “a fantastically exciting new world that has evolved over the last few years which is transforming the way cancer is treated.” Mr Goodfellow said: “All the data in all the indications is supporting the thesis that the immune system is absolutely central in the way that cancer evolves and has been treated. While people have thought that for a long time, the proof has been lacking, but the field has moved forward in leaps and bounds in the past few years.”
Two immunotherapy approaches
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze